Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Head And Neck Cancer Application Slated For Third Quarter

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bristol-Myers Squibb and ImClone plan to submit Erbitux for head and neck cancer in the third quarter after an independent review confirmed that a Phase III trial met its primary endpoint

You may also be interested in...



Erbitux head/neck cancer sBLA

Bristol-Myers Squibb and ImClone are requesting a priority review for their Aug. 29 Erbitux (cetuximab) sBLA for treatment of squamous cell carcinoma of the head and neck. The application proposes use in combination with radiation in locally or regionally advanced disease where platinum-based chemotherapy has failed or is inappropriate. The submission comes after the sponsors' June announcement that they would delay the sBLA until an independent review confirmed the positive results of a pivotal Phase III trial (1Pharmaceutical Approvals Monthly July 2005, p. 27). ImClone has also filed a marketing authorization application in Europe for the indication...

Erbitux head/neck cancer sBLA

Bristol-Myers Squibb and ImClone are requesting a priority review for their Aug. 29 Erbitux (cetuximab) sBLA for treatment of squamous cell carcinoma of the head and neck. The application proposes use in combination with radiation in locally or regionally advanced disease where platinum-based chemotherapy has failed or is inappropriate. The submission comes after the sponsors' June announcement that they would delay the sBLA until an independent review confirmed the positive results of a pivotal Phase III trial (1Pharmaceutical Approvals Monthly July 2005, p. 27). ImClone has also filed a marketing authorization application in Europe for the indication...

Erbitux head/neck cancer sBLA delay

Bristol-Myers Squibb and ImClone will delay submission of Erbitux (cetuximab) for head and neck cancer until the end of the year to allow for an independent review of a pivotal Phase III study (IMC-9815). The companies originally planned a second-quarter submission. The delay is needed "to conduct additional and independent analysis of the primary endpoint of...locoregional control," ImClone Chief Medical Officer Eric Rowinsky explained during an April 13 conference call. The trial's secondary endpoint of survival will not be subject to independent review, according to the company...

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel